These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36033988)

  • 1. Comparing the Characteristics of Mucormycosis Between Cases with and without COVID-19; a Cross-sectional Study.
    Sistanizad M; Haji Aghajani M; Haghighi M; Amini H; Pourhoseingholi A; Taherpour N; Ziaie S; Salarian S; Moradi O
    Arch Acad Emerg Med; 2022; 10(1):e56. PubMed ID: 36033988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucormycosis in pre-COVID-19 and COVID-19 era: A study of prevalence, risk factors and clinical features.
    Arjmand P; Bahrami M; Mohammadie ZE; Taherynejad M; Khorasani NY; Mehrad-Majd H; Roshanzamir I; Bakhshaee M
    Laryngoscope Investig Otolaryngol; 2022 Sep; 7(5):1343-50. PubMed ID: 36249085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucormycosis, New Causative Agents, and New Susceptible Populations: Review of Cases in a Tertiary Care Hospital in Iran (2007-2021).
    Darazam IA; Babamahmoodi A; Ebrahimi MJ; Moafi M; Dilmaghani NA; Mardani M; Shokouhi S; Gharehbagh FJ; Chalmiani EM; Shabani M; Bidari F; Jamali E; Khoshsirat S; Shahriari M; Sabeti S; Rahmani Z; Mousavinejad SA; Ebrahimzadeh K; Hallajnejad M
    Iran J Public Health; 2023 Nov; 52(11):2467-2473. PubMed ID: 38106820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: An observational study.
    Avatef Fazeli M; Rezaei L; Javadirad E; Iranfar K; Khosravi A; Amini Saman J; Poursabbagh P; Ghadami MR; Parandin MM; Dehghani A; Ahmadi Jouybari T; Mahdavian B; Eivazi N; Rezaei S; Rezaei A; Emami B; Haqgou M; Bozorgomid A; Sayad B
    Mycoses; 2021 Nov; 64(11):1366-1377. PubMed ID: 34252988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Serum Iron Studies in COVID Associated Mucormycosis with Stage of the Disease.
    Rao C; R M
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New-onset hyperglycaemia and prolonged systemic corticosteroids therapy in mild COVID-19 patients as major risk factors for invasive mucormycosis: a preliminary study.
    Khichar S; Samantaray S; Kumar D; Mobarsa V; Jain V; Sharma V; Soni K; Choudhury B; Goyal A; Shankar Meena D; Srinivasan S; Dutt N; Bhardwaj P; Agarwal A; Kumar Garg M; Misra S
    Curr Med Mycol; 2021 Sep; 7(3):22-28. PubMed ID: 35528622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation and Comparison of Mucormycosis Patients' Features Undergoing Functional Endoscopic Sinus Surgery Prior to and during the COVID-19 Pandemic: A Case-Control Study.
    Dehghanpisheh L; Eghbal M; Salari M; Shahriarirad R; Borzou N; Vatankhah P
    Int J Clin Pract; 2022; 2022():1248325. PubMed ID: 35693548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of hospital mortality among patients with COVID-19 in Tehran, Iran.
    Esfahanian F; SeyedAlinaghi S; Janfaza N; Tantuoyir MM
    SAGE Open Med; 2021; 9():20503121211051573. PubMed ID: 34676075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 associated mucormycosis in Assiut University Hospitals: a multidisciplinary dilemma.
    Farghly Youssif S; Abdelrady MM; Thabet AA; Abdelhamed MA; Gad MOA; Abu-Elfatth AM; Saied GM; Goda I; Algammal AM; Batiha GE; Abd El-Rady NM; Hetta HF; Kasem SM
    Sci Rep; 2022 Jun; 12(1):10494. PubMed ID: 35729170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between cumulative dose of immunosuppressive agents and COVID-19-associated mucormycosis: A multicenter cross-sectional study.
    Rastkar M; SeyedAlinaghi S; Asanjarani B; Siri G; Abdollahi H; Ghadami L; Hasibi M; Khodashahi R; Bagheri A; Asadollahi-Amin A
    Health Sci Rep; 2022 Nov; 5(6):e950. PubMed ID: 36439042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary bacterial infections in post-COVID-19 mucormycosis cases: a retrospective study at Imam Khomeini Hospital Complex, March 2020-April 2021.
    Meidani M; Zahak Miandoab S; Salami A; Jadidi S; Sohrabi M; Ebrahimi Alavijeh P; Ghaderkhani S; Emadi Koochak H; Salami Khaneshan A
    Iran J Microbiol; 2024 Jun; 16(3):293-298. PubMed ID: 39005610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing Characteristics of COVID-19-Associated Mucormycosis; a Case Series.
    Samimiardestani S; Irani S; Hasibi M; Seyedahadi M; Bastaninejad S; Firouzifar M; Mohammadi Ardehali M; Berijani S; Erfanian R; Kazemi MA; Etemadi-Aleagha A; Rahimi A; Karimi Yarandi K; Ahadi S
    Arch Acad Emerg Med; 2022; 10(1):e66. PubMed ID: 36381973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iranian patients co-infected with COVID-19 and mucormycosis: the most common predisposing factor, clinical outcomes, laboratory markers and diagnosis, and drug therapies.
    Molaei H; Shojaeefar E; Nemati E; Khedmat L; Mojtahedi SY; Jonaidi Jafari N; Izadi M; Einollahi B
    Infect Dis (Lond); 2022 Aug; 54(8):600-613. PubMed ID: 35389322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Analysis of Risk Factors of COVID-19 Associated Mucormycosis and Mortality Predictors: A Single-Center Study.
    Zirpe K; Pote P; Deshmukh A; Gurav SK; Tiwari AM; Suryawanshi P
    Cureus; 2021 Oct; 13(10):e18718. PubMed ID: 34790473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of Profile of Mucormycosis During the Second Wave of COVID-19 in a Tertiary Care Hospital.
    Kamath S; Kumar M; Sarkar N; Ahmed T; Sunder A
    Cureus; 2022 Jan; 14(1):e21054. PubMed ID: 35155019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Descriptive Epidemiology of COVID-19 Deaths during the First Wave of Pandemic in India: A Single-center Experience.
    Tendulkar P; Pandey P; Panda PK; Bhadoria AS; Kulshreshtha P
    Indian J Crit Care Med; 2022 Jan; 26(1):71-75. PubMed ID: 35110848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucormycosis and Covid-19 : Risk Factors, Clinical Presentation and Outcome in a Tertiary Care Centre in North India.
    A GA; Ashraf H; HaiderMehdi HS
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes and Covid Associated Mucormucormycosis-A Cross Sectional Study in Kilpauk Medical College.
    Pradeepkumar V
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of mucormycosis cases in COVID-19: Is it an unholy trilogy of COVID-19, diabetes mellitus, and corticosteroids?
    Kumar R; Misra AK; Dutta S; Gupta A; Kumar B; Charan J
    J Family Med Prim Care; 2022 Jun; 11(6):2573-2580. PubMed ID: 36119210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.